Find A Physician
Return to Center for Lymphoma and Myeloma Overview
More on Center for Lymphoma and Myeloma
Hospital News
Return to Center for Lymphoma and Myeloma Overview
More on Center for Lymphoma and Myeloma
- Bexxar Effective as First-Line Treatment for Non-Hodgkin's Lymphoma Patients When Used With Chemotherapy
- Children With Advanced Hodgkin's Disease Respond Favorably to New Drug Regimen
- Clinical Trial for a Novel Multiple Myeloma Vaccine Begins at New York Weill Cornell Medical Center
- Columbia Receives $3 Million Award From Pediatric Cancer Foundation for New Research Laboratory
- Combination of Abbreviated Chemotherapy with Radioactive Monoclonal Antibody Effective in Previously Untreated Non-Hodgkin's Lymphoma
- Coping With Chronic Cancer Pain
- Do Heart Disease and Cancer Have a Common Genetic Link?
- Dr. Selina Chen-Kiang Honored as Researcher of the Year by the Leukemia and Lymphoma Society
- Gleevec May Be Effective Against a Second Blood Disease, According to Study To Be Presented at Hematology Meeting
- Health Effects of Secondhand Smoke Studied in First-of-Its-Kind Series of Clinical Studies
- Helping Parents Do the Right Thing: New Guidelines on Umbilical Cord Blood Banking
- Integrative Therapies Program for Children with Cancer at Morgan Stanley Children's Hospital of NewYork-Presbyterian Receives Gift Commitment from Origins Natural Resources
- Latest Findings Presented at Second International Symposium on Pediatric Non-Hodgkin's Lymphoma
- Message to the Elderly: It's Never Too Late to Prevent Illness!
- Multiple Myeloma Oral Therapy REVLIMID Approved by FDA
- New Anti-Leukemia Drug Significantly Improves Survival Even for Patients With Late-Stage Disease, Study Finds
- New Book by Weill Cornell Psychiatrist Offers Insight and Hope for "Surviving Cancer Emotionally"
- NewYork-Presbyterian/Weill Cornell Creates World-Class Cancer Center
- NewYork-Presbyterian/Weill Cornell Multiple Myeloma Program Begins Clinical Trial of Promising New Chemotherapy Cocktail with Revlimid
- NewYork-Presbyterian/Weill Cornell Seeks Patients with Mantle Cell Lymphoma for Clinical Trial with Velcade (Bortezomib) for Injection
- NewYork-Presbyterian Hospital/Columbia University Medical Center Physician-Scientists Present at American Society of Clinical Oncology 44th Annual Meeting
- NewYork-Presbyterian Hospital's Weill Cornell Medical Center Announces Preliminary Lung Cancer Data Involving Patients Treated With Arthritis Medication
- NewYork-Presbyterian Hospital and Columbia University Medical Center Physicians-Scientists Present Latest Cancer Findings at American Society of Hematology Meeting
- NewYork-Presbyterian Hospital Oncologists, from Columbia, Weill Cornell, Co-Lead World's Largest Lymphoma Forum for Patients
- One of the Nation's Largest Portfolios of New Lymphoma Therapies Targets Diverse and Difficult Cancer
- The Seventh Issue of Cancer Prevention Has Arrived!
- Tumor Size Predicts Survival in Most Common Type of Lung Cancer
- Two Novel Biologics Studied for Multiple Myeloma
- Weill Cornell Medical College Wins $7.5 Million Grant From Leukemia Society To Study Multiple Myeloma
- Weill Cornell Physician-Scientists Present Latest Cancer and Blood Findings at American Society of Hematology (ASH) Meeting
- Weill Cornell Researchers Report "Encouraging" Results with First Combination Antibody Therapy for Lymphoma
Research and Clinical Trials
Return to Center for Lymphoma and Myeloma Overview
More on Center for Lymphoma and Myeloma
Health Library
Return to Center for Lymphoma and Myeloma Overview
More on Center for Lymphoma and Myeloma
- Acute Lymphocytic Leukemia
- Acute Myelogenous Leukemia
- Bone Marrow Transplantation
- Cancer: Overview of Diagnostic Procedures
- Cancer Overview
- Cancer Rehabilitation
- Cancer Treatment Protocols
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Cutaneous T-Cell Lymphoma
- Cytology
- External Beam Therapy
- Grading and Staging of Cancer
- Hodgkin's Disease
- Leukemia Overview
- Myeloma Bone Disease / Multiple Myeloma
- Non-Hodgkin's Lymphoma
Clinical Services
Return to Center for Lymphoma and Myeloma Overview
More on Center for Lymphoma and Myeloma
- Adult Bone Marrow Transplant
- Bladder Cancer
- Blood and Bone Marrow Transplant
- Blood Cancer
- Brain Cancer
- Center for Holistic Urology
- Colon Cancer
- Early Lung Cancer Action Program
- Edward S. Harkness Eye Institute
- Esophageal Cancer
- Eye Cancer
- Gastrointestinal Cancer
- Gynecological Cancer
- Head and Neck Cancer
- Hematology (Blood Disorders)
- Kidney Cancer
- Leukemia and Myeloproliferative Disease Center
- Liver Cancer
- Lung Cancer
- Mesothelioma
- Oncology (Cancer)
- Pancreatic and Biliary Cancer
- Pediatric Cancer
- Prostate Cancer
- Rectal Cancer
- Robert M. Ellsworth Ophthalmic Oncology Center
- Soft Tissue and Bone Cancer
- Spirit of Care Program
- Stomach Cancer
- Testicular Cancer
- Urologic Cancer
Center for Lymphoma and Myeloma
The Center for Lymphoma and Myeloma at NewYork-Presbyterian Hospital/Weill Cornell Medical Center is one of the largest treatment facilities for these diseases in the country, and has been cited as a National Center of Excellence by the Leukemia and Lymphoma Society of America. Calling on multidisciplinary collaboration with medical oncology, pathology, radiology, and nuclear medicine, the Center offers novel therapies, including biological agents and stem cell transplantation, and is among the leading programs in the world for immune-based monoclonal antibody therapies. The Center has numerous clinical trials of antibodies, and was the first to combine two different monoclonal antibodies to treat lymphomas. A major focus of efforts is developing new immunotherapies and combining antibodies with other novel biologic agents to improve treatment results while attempting to avoid the toxicity of chemotherapy.
The Center pioneered the growth of radiolabeled antibody treatment for lymphoma, and has conducted a significant number of institutional and multicenter clinical trials in this area. The Center also was among the first to combine chemotherapy with radiolabeled antibodies as part of initial therapy for patients newly diagnosed with lymphoma.
Several clinical trials also are underway to evaluate vaccines administered following chemotherapy to delay or prevent recurrence of tumor. The Center's B cell lymphoma program continues to attract patients from all over the world with its innovative immunological therapies. Over the past four years, over 400 patients have participated in the Center's clinical trials of new treatment modalities. The Center also led the way and published extensively on the use of nuclear medicine imaging and scanning techniques to monitor treatment.
Multiple myeloma is one of the most prevalent and difficult lymphatic malignancies to treat because virtually nothing is known about its molecular basis. In 2000, the Leukemia and Lymphoma Society awarded Weill Medical College of Cornell University a five-year, multimillion- dollar Specialized Center of Research (SCOR) grant to study the fundamental causes of multiple myeloma and develop therapeutic agents. A goal of the study is to understand how normal plasma cells develop and how the genes that regulate their development and transformation work in order to formulate new treatment for the disease.
The Center also is a leading treatment site for multiple myeloma, and has conducted several important new trials in this disease, including studies of the use of vaccine therapy and other new drugs that have demonstrated benefit for myeloma patients. The multidisciplinary team is experienced in addressing the wide variety of medical issues associated with myeloma, including bone disease and kidney problems.
